The Clinical Characteristics, Treatment and Prognosis of Tuberculosis-associated COPD

Summary

Chronic obstructive pulmonary disease (COPD) still imposes a substantial health and economic burden worldwide. Pulmonary tuberculosis has been confirmed as an important risk factor for COPD and this specific phenotype is thereby named as "tuberculosis-associated COPD". Although it is a generally accepted concept, several relevant problems need to be addressed, including how to define this phenotype more precisely, what the clinical characteristics and prognosis are as well as which kind of pharmacologic intervention is optimal.

In this study, tuberculosis-associated COPD patients (study group) and non-tuberculosis associated COPD patients (control group) are recruited. After collecting baseline information of participants, the investigators arrange for participants to follow up in the outpatient for reassessment with a scheduled interval of 6 months, which lasts for 1 year. Primary outcome of this study is the frequency of moderate/severe acute exacerbation of COPD during the follow-up of 12 months. By conducting a multicenter prospective cohort study in China, the researchers intend to investigate the clinical characteristics and prognostic predictors, explore plausible therapeutic regimens and promote precise diagnosis and treatment for tuberculosis-associated COPD.

Conditions

• COPD

Interventions

OTHER

previous pulmonary tuberculosis

Previous pulmonary tuberculosis is comprehensively evaluated by the self-reported medical history, T-SPOT.TB test and radiological findings.

Sponsors & Collaborators

• Peking University Shougang Hospital

  collaborator OTHER

• The First Affiliated Hospital of Guangzhou Medical University

  collaborator OTHER

• First Hospital of China Medical University

  collaborator OTHER

• West China Hospital

  collaborator OTHER

• Shanxi Bethune Hospital

  collaborator OTHER

• Tibet Autonomous Region People's Hospital

  collaborator OTHER

• Peking University Third Hospital

  lead OTHER

Principal Investigators

• Ying Liang, M.D. · Peking University Third Hhospital

Eligibility

Min Age

35 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2024-05-01

Primary Completion

2025-12-31

Completion

2025-12-31

Countries

• China

Study Locations